Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Henlius Signs $200 Million Deal with Intas for EU/Indian Rights to its Anti-PD-1

publication date: Oct 27, 2023

Shanghai Henlius Biotech out-licensed Europe/India rights for its anti-PD-1, Hansizhuang (serplulimab injection), to its partner Intas Pharmaceuticals in a $200 million deal. Intas will have development and commercialization rights to the drug for several indications including ES-SCLC and for a specific formulation of the drug. Henlius will be responsible for clinical development and manufacturing of the candidate. Intas will make a $45 million payment upfront, up to $46 million in regulatory milestones and $106 million in sales milestones, plus double-digit royalties on net profit. More details....

Stock Symbol: (HK: 2696)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here